Description
A peripherally restricted µ-opioid receptor antagonist (Ki = 10 nM; IC50s = 130.7 and 0.43 nM in rat brain membranes prepared with sodium chloride or water, respectively); selective for µ-opioid receptors over δ- and κ-opioid receptors (Kis = 630.95 and 31.62 nM, respectively); decreases spontaneous mechanical activity in ileum isolated from morphine-treated guinea pigs when administered at doses of 1 and 10 µM; does not inhibit heroin self-administration in rats; does not induce withdrawal syndrome in morphine-dependent rhesus monkeys when administered at doses up to 32 mg/kg
Formal name: 17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-17-methyl-6-oxo-morphinanium, monobromide
Synonyms: MRZ 2663BR|Naltrexone methylbromide
Molecular weight: 436.3
CAS: 73232-52-7
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Behavioral Neuroscience|Addiction Research